Who Owns Prestige Consumer Healthcare Company?

Who Owns Prestige Consumer Healthcare?

Prestige Consumer Healthcare Inc. was formed in 1996 through a significant merger, establishing a foundation in the over-the-counter (OTC) product market. Headquartered in Tarrytown, New York, the company has since grown into a prominent entity within the North American and Australian OTC healthcare sectors.

The company's strategic focus involves acquiring, developing, and marketing a wide array of brand-name products, spanning categories like feminine care, eye care, oral care, and pain relief, including popular items like Prestige Consumer Healthcare BCG Matrix.

As of fiscal year 2024, the company reported revenues reaching $1,125.4 million, underscoring its significant market presence and operational scale.

Prestige Consumer Healthcare Inc. was formed in 1996 through a significant merger. Its early structure involved key executives guiding its initial operations from its Purchase, New York base.

Company Formation

Established in 1996, the company emerged from the consolidation of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company.

Early Strategy

The company's initial strategy focused on acquiring and revitalizing established brands that were considered non-core by larger corporations.

Founding Team

While specific founder names are not widely publicized, early leadership comprised executives instrumental in shaping the company's initial direction.

Original Location

The company's initial headquarters were situated in Purchase, New York, marking its early operational base.

Private Equity Involvement

In 2004, a significant ownership shift occurred when MidOcean Partners sold its stake in Prestige Brands to GTCR Golder Rauner.

Funding Details

Specific details regarding initial capital, funding sources, and early equity distributions are not readily available in public records.

The company, initially known as Prestige Brands Holdings, Inc., was formally established in 1999 with a clear business model. This model centered on identifying and acquiring well-known brands that were underutilized by their parent companies, aiming to rejuvenate them through strategic management and marketing. This approach laid the groundwork for its future growth and market positioning, as detailed in discussions about the Growth Strategy of Prestige Consumer Healthcare.

Key Ownership Milestones

Understanding the ownership history is crucial for grasping the company's trajectory. Early ownership changes reflect strategic shifts and investment interests.

• Formation in 1996 through a multi-company merger.
• Establishment of Prestige Brands Holdings, Inc. in 1999.
• Acquisition by GTCR Golder Rauner from MidOcean Partners in 2004.
• Focus on acquiring and revitalizing neglected brands.
• Limited public disclosure on initial funding and equity splits.

Complete Prestige Consumer Healthcare Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Prestige Consumer Healthcare Inc. has seen significant shifts in its ownership structure, largely influenced by strategic acquisitions. The company, traded on the NYSE under PBH, has a history of expanding its brand portfolio through key purchases, impacting its overall financial and ownership dynamics.

Institutional investors are the dominant force in Prestige Consumer Healthcare's ownership, holding a substantial majority of the company's shares. As of early 2025, these institutions collectively own approximately 84.8% of the company's stock, with some reports indicating as high as 99.95%. This significant institutional backing underscores the company's position in the public market and influences its strategic direction. The company's net debt stood at approximately $0.9 billion as of March 31, 2025, with a leverage ratio of 2.4x.

Key Shareholders of Prestige Consumer Healthcare

Institutional investors represent the largest segment of Prestige Consumer Healthcare's ownership. Individual stakeholders also hold a notable, albeit smaller, portion of the company's shares.

• Institutional Ownership: Approximately 84.8% (as of early 2025)
• Major Institutional Investors: BlackRock, Inc., The Vanguard Group, Inc., State Street Global Advisors, Inc., Victory Capital Management Inc., Invesco Ltd., Dimensional Fund Advisors LP
• BlackRock, Inc. Ownership: 16.56% (as of early 2025)
• The Vanguard Group, Inc. Ownership: 11.40% (as of early 2025)
• Insider Ownership: Approximately 0.8% to 1.40% (valued at ~US$25 million as of January 2024)
• Largest Individual Shareholder: David Donnini, owning 10.04 million shares (20.31% as of early 2025)

The ownership evolution of Prestige Consumer Healthcare has been shaped by strategic growth through acquisitions. While institutional investors are the primary stakeholders, understanding the company's Mission, Vision & Core Values of Prestige Consumer Healthcare provides context for its strategic decisions and how they might align with shareholder interests. The company's history includes significant transactions, such as the 2011 purchase of 17 brands from GlaxoSmithKline for $660 million and the 2021 acquisition of Akorn's Consumer Health unit for $230 million. These moves highlight a strategy of portfolio expansion, which in turn influences the company's financial structure and, consequently, its ownership dynamics.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors at Prestige Consumer Healthcare Inc. is instrumental in guiding the company's strategic direction and corporate governance. Ronald M. Lombardi holds the key positions of Chairman, President, and Chief Executive Officer, a role he has occupied since June 2015, and has served as Chairman since May 2017. Christine Sacco, the Chief Financial Officer since 2016, also took on the responsibilities of Chief Operating Officer in January 2025, further solidifying the leadership team.

The composition of the board includes independent directors, such as James C. D'Arecca and Sheila A. Hopkins, who contribute to balanced decision-making and oversight. Celeste A. Clark, Ph.D. was notably recognized by the National Association of Corporate Directors in 2023. While specific details regarding board members representing major institutional shareholders are not publicly detailed, the company encourages all stockholders to exercise their voting rights. Prestige Consumer Healthcare Inc. operates under a typical one-share-one-vote structure, as indicated by its proxy statements, with no public disclosures suggesting dual-class shares or special voting rights that would concentrate control.

Understanding Voting Power at Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc. operates on a standard voting structure, emphasizing shareholder participation. The company's governance relies on the principle of one share, one vote.

• Shareholders are encouraged to vote their shares.
• Voting can occur whether shares are held directly or through a broker.
• Proxy statements, like the 2025 Proxy Statement, detail voting matters.
• No dual-class share structures or special voting rights are publicly disclosed.
• This structure ensures broad shareholder influence on company decisions.

Understanding the board's composition and voting power is key to grasping Prestige Consumer Healthcare ownership. For a deeper dive into the competitive landscape, consider the Competitors Landscape of Prestige Consumer Healthcare. The company's financial reporting and ownership disclosures provide transparency for investors and stakeholders interested in Prestige Consumer Healthcare investors and Prestige Consumer Healthcare stakeholders.

Prestige Consumer Healthcare Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

In recent years, Prestige Consumer Healthcare Inc. has maintained a strong focus on returning value to its shareholders through strategic capital allocation, notably share repurchases. The company announced a significant new share repurchase program in May 2024, authorizing up to $300 million in common stock buybacks, reflecting a commitment to managing its ownership structure and enhancing shareholder equity.

The company's financial performance in fiscal year 2025 saw record revenues of $1,137.8 million, with adjusted diluted EPS reaching $4.52, a 7.4% increase year-over-year. While the first quarter of fiscal 2025 experienced a 4.4% revenue decrease to $267.1 million, attributed to supply chain issues and category-specific declines, the full-year outlook remains robust. Prestige Consumer Healthcare reaffirmed its fiscal 2025 revenue projection between $1.125 billion and $1.140 billion, anticipating adjusted EPS growth of 5% to 6%.

Shareholder Value Focus

Prestige Consumer Healthcare has actively engaged in share repurchase programs, demonstrating a commitment to enhancing shareholder value. The company's strategy includes disciplined capital allocation, with significant buybacks authorized and executed.

Financial Performance and Outlook

The company achieved record revenues in fiscal year 2025 and anticipates continued adjusted EPS growth. Despite some Q1 challenges, the full-year financial outlook remains positive, underscoring operational resilience.

Insider Trading Activity

Over the past 12 months, insider trading activity has indicated net selling. Key executives, including the CEO and CFO, have sold shares, a trend investors may monitor for underlying reasons, though personal financial planning is a common driver.

Capital Allocation and Growth Strategy

Beyond share repurchases, the company's capital allocation for fiscal 2025 includes M&A and deleveraging, with net debt reduced to approximately $0.9 billion as of March 31, 2025. International revenue growth is also a key long-term objective, increasing to 15.6% of total revenues in fiscal 2025. Understanding the Marketing Strategy of Prestige Consumer Healthcare can provide further context on growth drivers.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE